Xalkori Capsule, Coated Pellets
Product Images NDC 0069-0507
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Xalkori (NDC 0069-0507). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Xalkori 02)
This seems to be a table showing survival probabilities in a clinical trial comparing XALKORI to chemotherapy. The Hazard Ratio is 0.45 which indicates that the group treated with XALKORI had a better survival outcome. The median survival time for the XALKORI group was 10.9 months versus 7.0 months for the chemotherapy group. The table also shows the number of subjects at risk for each group.*
Figure 2 (Xalkori 03)
This is a chart with data comparing the median progression-free survival of 173 individuals administered XALKORI versus 174 individuals receiving chemotherapy. The chart shows that the median progression-free survival for XALKORI was 7.7 months whereas chemotherapy had a median of 3.0 months. The data is presented in a hazard ratio format with a 95% Cl of 0.37-0.64 and p<0.001. Further, the graph shows progression-free survival probability over time for both treatments. The XALKORI group showed a survival probability of approximately 80%, and the chemotherapy group showed a survival probability of approximately 60% over the same duration.*
Logo (Xalkori 04)
Principal Display Panel (250 mg Capsule Bottle Label)
Principal Display Panel (200 mg Capsule Bottle Label)
Store crizotinib capsules at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F) in tight containers as per the USP guidelines. The medication should always be dispensed enclosed per the guide to each patient. Each capsule of XALKORI contains 250 mg of crizotinib. The dosage and use of the medication should be as prescribed in the accompanying prescribing information. Pfizer Labs, a division of Pfizer Inc, distributes the medication, and it is manufactured in Ireland. The capsules should be swallowed whole.*
Xalkori 07
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.